Drug selection and timing of initiation of treatment in early Parkinson's disease

Annals of Neurology

Volumn 64, Issue SUPPL. 2, 2008, Pages

  Schapira, Anthony H V ^a,c   Olanow, C Warren ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BENZATROPINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE;

AKATHISIA; ANOREXIA; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DAYTIME SOMNOLENCE; DIARRHEA; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG WITHDRAWAL; DYSKINESIA; FIBROSIS; HALLUCINOSIS; HUMAN; HYPERSEXUALITY; INSOMNIA; LIVER TOXICITY; MONOTHERAPY; MOTOR PERFORMANCE; NAUSEA AND VOMITING; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PERICARDIUM FIBROSIS; PERIPHERAL EDEMA; PERITONEAL FIBROSIS; PLEURAL FIBROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOMNOLENCE; THERAPY DELAY; TREMOR; UNSPECIFIED SIDE EFFECT; URINE COLOR; VALVULAR HEART DISEASE;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; DOPAMINE AGONISTS; HUMANS; INDANS; LEVODOPA; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TIME FACTORS;

EID: 58349085532     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21460     Document Type: Review

References (91)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-535.
2. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
3. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-596.
4. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
5. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(suppl 5):1-88.
6. Schapira AH, Bezard E, Brotchie J, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 2006;5:845-854.
7. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
8. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001;8:95-100.
9. Schapira AH. The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Mov Disord. 2008;23 Suppl 3: S515-20.
10. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005;4:605-610.
11. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
12. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000;15:869-872.
13. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-1381.
14. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41(2 pt 1):202-205.
15. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
16. Olanow CW, Schapira AHV, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000;23:S117-S126.
17. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine receptor stimulation in the treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
18. Olanow CW. Levodopa dopamine replacement strategies in Parkinson's disease - future directions. Mov Disocd 2008;23:S613-22.
19. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
20. Jorga KM. COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin Neuropharmacol 1998; 21:S9-S16.
21. Kurth MC, Adler CH, St Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87.
22. Adler CH, Singer C, O'Brien C et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998;55:1089-1095.
23. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet 1998;352:958.
24. Olanow CW, Watkins PB. Tolcapone 2007: an efficacy and safety review. Clin Neuropharmacol 2007;30:287-294.
25. Korlipara LV, Cooper JM, Schapira AH. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology 2004;46:562-569.
26. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Infusion of levodopa methyl ester in patients with advanced PD: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
27. Sage JI, Trooskin S, Sonsalla PK, et al. Long term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-89.
28. Bet L, Bareggi SR, Pacei F, Bondiolotti G, Meola G, Schapira AH. Bimodal administration of entacapone in Parkinson's disease patients improves motor control. Eur J Neurol 2008;15(3):268-73.
29. Smith LA, Jackson MJ, Al-Barghouthy G, et al. Multiple small doses of levodopa plus entacapone produces continuous dopaminergic stimulation and reduces dyskinesia induction in MPTP-treated drug naïve primates. Mov Disord 2005;20:306-314.
30. Staal-Schreinemachers AL, Wesseling H, Kamphuis DJ, et al. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology 1986;36:291-293.
31. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997;48:363-368.
32. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55(suppl 1):23-30.
33. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999;53:573-579.
34. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA 1997;278:125-130.
35. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
36. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999;53:364-370.
37. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997;49:393-399.
38. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-1728.
39. Hoehn MM, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985;35:199-206.
40. Toyokura Y, Mizuno Y, Kase M, et al. Effects of bromocriptine on parkinsonism. A nation-wide collaborative double-blind study. Acta Neurol Scand 1985;72:157-170.
41. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785-788.
42. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
43. Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson's disease. Neurology 1985;35:291-295.
44. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-1065.
45. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168.
46. Poewe W, Giladi N, Boothman B, et al. Rotigotine transdermal system in patients with advanced-stage Parkinson's disease as adjunctive therapy to levodopa: results of a placebo- and pramipexole-controlled trial. Mov Disord 2006;21:S48.
47. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
48. Olanow CW. Scientific basis for the current treatment of Parkinson's disease. Annu Rev Med 2004;55:41-60.
49. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
50. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
51. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006;21:343-353.
52. Marti Masso JF, Montastruc JL, PKDS009 Study Group. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004;18:733-746.
53. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006;21:1844-1850.
54. Schapira AH. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol 2002;9(suppl 3):7-14.
55. Nair VD, Olanow CW, Sealfon SC. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 2003;373:25-32.
56. Iravani MM, Haddon CO, Cooper JM, et al. Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 2006;96:1315-1321.
57. Whone A, Watts R, Stoessl J, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 2003;54:93-101.
58. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of Pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
59. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-389.
60. Jennings DL, Tabamo R, Seibyl JP, Marek K. INSPECT: investigating the effect of short-term treatment with pramipexole or levodopa on 123Iβ-CIT-SPECT imaging. Mov Disord 2007;22:113.
61. Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 2003;26:109-111.
62. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-1183.
63. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
64. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006; 67:1225-1229.
65. Frucht S, Rogers JD, Greene PD, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910.
66. Schapira AH. Excessive daytime sleepiness in Parkinson's disease. Neurology 2004;63(8 suppl 3):S24-S27.
67. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61:422-423.
68. Olanow CW. Rationale for considering that Propargylamines might be Neuroprotective in Parkinson's disease. Neurology 2006;66(10 suppl 4):S69-S79.
69. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
70. Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004;329:593.
71. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.
72. Palhagen S, Heinonen E, Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66:1200-1206.
73. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943.
74. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-566.
75. Schapira A, Bate G, Kirkpatrick P. Rasagline. Nat Rev Drug Discov 2005;4(8):625-626.
76. Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 1992;115(pt 6):1701-1725.
77. Friedman JH, Koller WC, Lannon MC, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997;48:1077-1081.
78. Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969;208:1168-1170.
79. Factor SA, Molho ES. Transient benefit of amantadine in Parkinson's disease: the facts about the myth. Mov Disord 1999;14:515-517.
80. Parkes JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1974;37:422-426.
81. Walker JE, Albers JW, Tourtellotte WW, et al. A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson's disease. J Chronic Dis 1972;25:149-182.
82. Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007;64:1083-1088.
83. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-562.
84. Aminoff MJ. Treatment should not be initiated too soon in Parkinson's disease. Ann Neurol 2006;59:562-564.
85. Shapira AHV, Obeso JA. Reply. Ann Neurol 2006;59:564-565.
86. Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-230.
87. Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 2000;9:87-100.
88. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004;291:358-364.
89. Lew M, Hauser R, Hurtig H, et al. Long-term efficacy of rasagiline in Parkinson' s disease. Mov Disord 2005;20:250.
90. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006;253:601-607.
91. Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2006;2:382-392.